Teyi Pharmaceutical Group announced that in the third quarter of 2024, the company achieved revenue of approximately 0.142 billion yuan, a year-on-year decrease of 31.44%. The net income attributable to shareholders of the listed company was 3.3204 million yuan, a year-on-year decrease of 90.87%. The company stated that the main reason for the decline in performance was the decrease in sales of traditional chinese medicine with relatively high gross margin and the short-term impact of marketing organization transformation.